536 related articles for article (PubMed ID: 17892163)
1. Regulations for vaccines against emerging infections and agrobioterrorism in the United States of America.
Elsken LA; Carr MY; Frana TS; Brake DA; Garland T; Smith K; Foley PL
Rev Sci Tech; 2007 Aug; 26(2):429-41. PubMed ID: 17892163
[TBL] [Abstract][Full Text] [Related]
2. Regulatory considerations for emergency use of non-USDA licensed vaccines in the United States.
Hill RE; Foley PL; Carr MY; Elsken LA; Gatewood DM; Ludemann LR; Wilbur LA
Dev Biol (Basel); 2003; 114():31-52. PubMed ID: 14677675
[TBL] [Abstract][Full Text] [Related]
3. Translating research into licensed vaccines and validated and licensed diagnostic tests.
Hill RE; Foley PL; Clough NE; Ludemann LR; Murtle DC
Dev Biol (Basel); 2013; 135():53-8. PubMed ID: 23689883
[TBL] [Abstract][Full Text] [Related]
4. Licensing veterinary biologics in the United States.
Espeseth DA
Dev Biol Stand; 1992; 79():17-25. PubMed ID: 1286752
[TBL] [Abstract][Full Text] [Related]
5. Regulation of veterinary biological products for fish in the United States.
Birnbaum NG
Dev Biol Stand; 1997; 90():335-40. PubMed ID: 9270861
[TBL] [Abstract][Full Text] [Related]
6. The Unites States Department of Agriculture Regulation of Veterinary Biological Products. The use of prelicensing evaluation and postlicensing monitoring to achieve regulatory compliance.
Hill RE; Randall DC
Qual Assur; 1995 Dec; 4(4):323-8. PubMed ID: 8890360
[TBL] [Abstract][Full Text] [Related]
7. Regulatory considerations for marker vaccines and diagnostic tests in the U.S.
Foley PL; Hill RE
Biologicals; 2005 Dec; 33(4):253-6. PubMed ID: 16257538
[TBL] [Abstract][Full Text] [Related]
8. Current USDA procedures for licensing biotechnology-derived veterinary biologicals.
Gay CG
Dev Biol Stand; 1992; 79():65-74. PubMed ID: 1286767
[TBL] [Abstract][Full Text] [Related]
9. Regulation of conditionally licensed biologicals in the United States.
Hill RE
Dev Biol (Basel); 2004; 117():147-52. PubMed ID: 15597632
[TBL] [Abstract][Full Text] [Related]
10. Regulatory requirements for vaccine authorisation.
Jones PG; Cowan G; Gravendyck M; Nagata T; Robinson S; Waits M
Rev Sci Tech; 2007 Aug; 26(2):379-93. PubMed ID: 17892159
[TBL] [Abstract][Full Text] [Related]
11. Confirming the safety characteristics of recombinant vectors used in veterinary medicine: a regulatory perspective.
Gay CG; Roth HJ
Dev Biol Stand; 1994; 82():93-105. PubMed ID: 7958487
[TBL] [Abstract][Full Text] [Related]
12. Technical requirements of veterinary vaccines for registration--FEDESA's point of view.
Watson J
Dev Biol Stand; 1992; 79():51-63. PubMed ID: 1286766
[No Abstract] [Full Text] [Related]
13. History of regulatory requirements for poultry biologics in the United States, 1970s to 1990s.
Espeseth DA; Lasher H
Avian Dis; 2013 Jun; 57(2):167-71. PubMed ID: 24689169
[TBL] [Abstract][Full Text] [Related]
14. Presentation of the directive 81/852/EEC (92/18) safety testing.
Vannier P
Dev Biol Stand; 1992; 79():47-50. PubMed ID: 1286765
[TBL] [Abstract][Full Text] [Related]
15. Inspection of veterinary biologics in the United States.
Randall DC
Dev Biol Stand; 1992; 79():163-70. PubMed ID: 1286751
[TBL] [Abstract][Full Text] [Related]
16. Authorisation within the European Union of vaccines against antigenically variable viruses responsible for major epizootic diseases.
Mackay DK
Rev Sci Tech; 2007 Aug; 26(2):421-8. PubMed ID: 17892162
[TBL] [Abstract][Full Text] [Related]
17. Testing of veterinary biologics in the United States.
Bunn TO
Dev Biol Stand; 1992; 79():187-92. PubMed ID: 1286757
[TBL] [Abstract][Full Text] [Related]
18. Comparison of requirements in the European Union and United States of America for pre-clinical viral safety testing of veterinary vaccines.
Sheridan S; Coughlin J
Biologicals; 2010 May; 38(3):340-5. PubMed ID: 20400329
[TBL] [Abstract][Full Text] [Related]
19. National considerations in the Nordic countries regarding vaccine licensing.
Gunnarsson E; Lund A; Høy T; Larsson B; Sihvonen L
Acta Vet Scand Suppl; 1996; 90():85-7. PubMed ID: 8996893
[No Abstract] [Full Text] [Related]
20. Challenges and opportunities in developing and marketing vaccines for OIE List A and emerging animal diseases.
Gay CG; Salt J; Balaski C
Dev Biol (Basel); 2003; 114():243-50. PubMed ID: 14677694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
